开云app官网登录入口网页版-官方正版

#ERR#

42篇内容 | 1688人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1703604, encodeId=6c131e0360494, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=JACC-Asia：来自CHERRY研究的结果：中国动脉粥样硬化心血管风险预测模型的评价, objectType=article, longId=293788, objectId=e58e293e8852, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e58e293e8852, replyNumber=0, likeNumber=79, createdTime=2022-07-12, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e58e293e8852, moduleTitle=JACC-Asia：来自CHERRY研究的结果：中国动脉粥样硬化心血管风险预测模型的评价, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e58e293e8852)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703605, encodeId=e5871e03605b6, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Xlear与Dr. Ferrer BioPharma合作，向用户提供更佳鼻腔卫生体验, objectType=article, longId=727374, objectId=ef9de27374d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef9de27374d3, replyNumber=0, likeNumber=61, createdTime=2022-09-30, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef9de27374d3, moduleTitle=Xlear与Dr. Ferrer BioPharma合作，向用户提供更佳鼻腔卫生体验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ef9de27374d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703600, encodeId=c2e01e0360025, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=PierreRobin序列征患儿行下颌骨牵引成骨术困难气道处理一例, objectType=article, longId=199470, objectId=c39b1994e0e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c39b1994e0e1, replyNumber=0, likeNumber=78, createdTime=2021-07-14, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c39b1994e0e1, moduleTitle=PierreRobin序列征患儿行下颌骨牵引成骨术困难气道处理一例, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c39b1994e0e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703602, encodeId=7f3a1e03602ed, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle= J Am Coll Cardiol：全新综述文章建议，Pesco-Mediterranean饮食应成为保护心血管健康饮食的黄金标准, objectType=article, longId=200878, objectId=89a72008e877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89a72008e877, replyNumber=0, likeNumber=78, createdTime=2021-04-02, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89a72008e877, moduleTitle= J Am Coll Cardiol：全新综述文章建议，Pesco-Mediterranean饮食应成为保护心血管健康饮食的黄金标准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=89a72008e877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703603, encodeId=36221e0360331, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Ferring和Rebiotix呈报的标志性3期数据显示，在研RBX2660减少艰难梭菌反复感染的有效性优于安慰剂, objectType=article, longId=211818, objectId=768c211818c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=768c211818c9, replyNumber=0, likeNumber=93, createdTime=2021-11-17, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=768c211818c9, moduleTitle=Ferring和Rebiotix呈报的标志性3期数据显示，在研RBX2660减少艰难梭菌反复感染的有效性优于安慰剂, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=768c211818c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703601, encodeId=72d61e036013b, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Cell Death Dis：类泛素化修饰负调节ERRβ促进乳腺癌的发生发展, objectType=article, longId=200184, objectId=f62120018401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f62120018401, replyNumber=0, likeNumber=69, createdTime=2021-07-16, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f62120018401, moduleTitle=Cell Death Dis：类泛素化修饰负调节ERRβ促进乳腺癌的发生发展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f62120018401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703598, encodeId=83431e035980c, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Oncologist：许建民教授发现CERR得分能良好评估结直肠癌肝转移手术后复发状况, objectType=article, longId=194266, objectId=029b19426680, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=029b19426680, replyNumber=0, likeNumber=63, createdTime=2020-05-26, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=029b19426680, moduleTitle=Oncologist：许建民教授发现CERR得分能良好评估结直肠癌肝转移手术后复发状况, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=029b19426680)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703597, encodeId=c2371e0359704, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=如何通俗地理解Family-wise error rate(FWER)和False discovery rate(FDR), objectType=article, longId=188433, objectId=3b6e188433e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b6e188433e0, replyNumber=0, likeNumber=62, createdTime=2020-12-17, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b6e188433e0, moduleTitle=如何通俗地理解Family-wise error rate(FWER)和False discovery rate(FDR), moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3b6e188433e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703599, encodeId=17961e0359929, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=结直肠癌肝转移时复发风险综合评估得分（CERR Score）, objectType=article, longId=194279, objectId=a6b01942e96e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6b01942e96e, replyNumber=0, likeNumber=61, createdTime=2021-02-21, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6b01942e96e, moduleTitle=结直肠癌肝转移时复发风险综合评估得分（CERR Score）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a6b01942e96e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703594, encodeId=e3c21e035949b, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, objectType=article, longId=178542, objectId=bc501e854207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc501e854207, replyNumber=0, likeNumber=85, createdTime=2020-05-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc501e854207, moduleTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bc501e854207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703595, encodeId=b2171e0359580, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Error bar是选择标准差还是置信区间？, objectType=article, longId=180742, objectId=c0c7180e4222, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0c7180e4222, replyNumber=0, likeNumber=77, createdTime=2019-11-11, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0c7180e4222, moduleTitle=Error bar是选择标准差还是置信区间？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c0c7180e4222)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703596, encodeId=9fa61e0359615, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Verrica制药宣布FDA批准VP-102的新药申请，用于治疗感染性软疣, objectType=article, longId=183716, objectId=998c183e16c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=998c183e16c2, replyNumber=0, likeNumber=73, createdTime=2020-01-17, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=998c183e16c2, moduleTitle=Verrica制药宣布FDA批准VP-102的新药申请，用于治疗感染性软疣, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=998c183e16c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703592, encodeId=e23f1e0359292, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=2019年美国皮肤病学会（AAD）年会：Verrica制药公布了VP-102的全新临床试验结果, objectType=article, longId=161606, objectId=6c5f16160651, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c5f16160651, replyNumber=0, likeNumber=73, createdTime=2019-11-10, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c5f16160651, moduleTitle=2019年美国皮肤病学会（AAD）年会：Verrica制药公布了VP-102的全新临床试验结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6c5f16160651)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703590, encodeId=67781e03590b8, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Merrimack停止了MM-121的SHERLOC研究, objectType=article, longId=151516, objectId=615715151657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=615715151657, replyNumber=0, likeNumber=77, createdTime=2018-10-26, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=615715151657, moduleTitle=Merrimack停止了MM-121的SHERLOC研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=615715151657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703587, encodeId=66691e035875d, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Perrigo计划将处方药业务分开, objectType=article, longId=146301, objectId=9a6c146301ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a6c146301ca, replyNumber=0, likeNumber=81, createdTime=2019-05-13, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a6c146301ca, moduleTitle=Perrigo计划将处方药业务分开, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9a6c146301ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703589, encodeId=0c911e035892c, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Ferring Pharmaceuticals在英国推出睾酮替代疗法Testavan治疗性腺功能减退, objectType=article, longId=149625, objectId=38d4149625b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38d4149625b6, replyNumber=0, likeNumber=81, createdTime=2019-07-11, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38d4149625b6, moduleTitle=Ferring Pharmaceuticals在英国推出睾酮替代疗法Testavan治疗性腺功能减退, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=38d4149625b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703593, encodeId=78fa1e0359320, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=NEJM：Lemierre综合症-病例报道, objectType=article, longId=162680, objectId=cfc1162680f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfc1162680f6, replyNumber=0, likeNumber=78, createdTime=2019-04-30, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfc1162680f6, moduleTitle=NEJM：Lemierre综合症-病例报道, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cfc1162680f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703591, encodeId=3c2f1e035913f, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Luqa制药和Ferrer制药宣布联合推进亚洲皮肤病的治疗, objectType=article, longId=151531, objectId=e48e151531be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e48e151531be, replyNumber=0, likeNumber=61, createdTime=2019-08-10, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e48e151531be, moduleTitle=Luqa制药和Ferrer制药宣布联合推进亚洲皮肤病的治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e48e151531be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703586, encodeId=4fc61e03586e4, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Merrimack在中期研究失败后停止开发实验性胰腺癌治疗药物, objectType=article, longId=141737, objectId=6982141e37fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6982141e37fd, replyNumber=0, likeNumber=101, createdTime=2019-01-21, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6982141e37fd, moduleTitle=Merrimack在中期研究失败后停止开发实验性胰腺癌治疗药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6982141e37fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703588, encodeId=b8131e03588f4, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, objectTitle=Blood：Erythroferrone（ERFE）可抑制BMP5/6/7诱导的铁调素合成, objectType=article, longId=146702, objectId=5e96146e023b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e96146e023b, replyNumber=0, likeNumber=89, createdTime=2019-03-23, rootId=0, userName=surilei, userId=a72d30527892, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e96146e023b, moduleTitle=Blood：Erythroferrone（ERFE）可抑制BMP5/6/7诱导的铁调素合成, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5e96146e023b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

ERR

2020-05-29

surilei (审核中...)

前往app查看评论内容

#ERR#

JACC-Asia：来自CHERRY研究的结果：中国动脉粥样硬化心血管风险预测模型的评价

2022-07-12

surilei (审核中...)

前往app查看评论内容

#ERR#

Xlear与Dr. Ferrer BioPharma合作，向用户提供更佳鼻腔卫生体验

2022-09-30

surilei (审核中...)

前往app查看评论内容

#ERR#

PierreRobin序列征患儿行下颌骨牵引成骨术困难气道处理一例

2021-07-14

surilei (审核中...)

前往app查看评论内容

#ERR#

J Am Coll Cardiol：全新综述文章建议，Pesco-Mediterranean饮食应成为保护心血管健康饮食的黄金标准

2021-04-02

surilei (审核中...)

前往app查看评论内容

#ERR#

Ferring和Rebiotix呈报的标志性3期数据显示，在研RBX2660减少艰难梭菌反复感染的有效性优于安慰剂

2021-11-17

surilei (审核中...)

前往app查看评论内容

#ERR#

Cell Death Dis：类泛素化修饰负调节ERRβ促进乳腺癌的发生发展

2021-07-16

surilei (审核中...)

前往app查看评论内容

#ERR#

Oncologist：许建民教授发现CERR得分能良好评估结直肠癌肝转移手术后复发状况

2020-05-26

surilei (审核中...)

前往app查看评论内容

#ERR#

如何通俗地理解Family-wise error rate(FWER)和False discovery rate(FDR)

2020-12-17

surilei (审核中...)

前往app查看评论内容

#ERR#

结直肠癌肝转移时复发风险综合评估得分（CERR Score）

2021-02-21

智智灵药 (审核中...)

前往app查看评论内容

#ERR#

诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功

2020-05-19

surilei (审核中...)

前往app查看评论内容

#ERR#

Error bar是选择标准差还是置信区间？

2019-11-11

surilei (审核中...)

前往app查看评论内容

#ERR#

Verrica制药宣布FDA批准VP-102的新药申请，用于治疗感染性软疣

2020-01-17

surilei (审核中...)

前往app查看评论内容

#ERR#

2019年美国皮肤病学会（AAD）年会：Verrica制药公布了VP-102的全新临床试验结果

2019-11-10

surilei (审核中...)

前往app查看评论内容

#ERR#

Merrimack停止了MM-121的SHERLOC研究

2018-10-26

surilei (审核中...)

前往app查看评论内容

#ERR#

Perrigo计划将处方药业务分开

2019-05-13

surilei (审核中...)

前往app查看评论内容

#ERR#

Ferring Pharmaceuticals在英国推出睾酮替代疗法Testavan治疗性腺功能减退

2019-07-11

surilei (审核中...)

前往app查看评论内容

#ERR#

NEJM：Lemierre综合症-病例报道

2019-04-30

surilei (审核中...)

前往app查看评论内容

#ERR#

Luqa制药和Ferrer制药宣布联合推进亚洲皮肤病的治疗

2019-08-10

surilei (审核中...)

前往app查看评论内容

#ERR#

Merrimack在中期研究失败后停止开发实验性胰腺癌治疗药物

2019-01-21

surilei (审核中...)

前往app查看评论内容

#ERR#

Blood：Erythroferrone（ERFE）可抑制BMP5/6/7诱导的铁调素合成

2019-03-23

科室
- - 订阅+
  - 更多科室
工具
服务